Upstream Bio Launches With $200M Series A Financing To Advance Novel Therapeutics For Allergic And Inflammatory Diseases

Jun 02, 2022•about 3 years ago

Amount Raised

$200 Million

Round Type

series a

WalthamBiotechnologyHealth Care

Description

Upstream Bio, a biotech company focused on inflammation, today debuted with a $200 million Series A financing. The funding will allow Upstream to advance the company’s lead program UPB-101, a clinical-stage monoclonal antibody targeting the TSLP receptor, and build a pipeline of assets to address immune-mediated diseases. The Series A round was led jointly by OrbiMed and Maruho Co., Ltd. with participation from Access Biotechnology, Decheng Capital, HBM Healthcare Investments, TCG X, Omega Funds, Samsara BioCapital, and Altshuler Shaham Provident Funds Ltd.

Company Information

Company

Upstream Bio

Location

Waltham, Massachusetts, United States

About

At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. We are leveraging our diverse roots and the team’s substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. https://www.upstreambio.com/

Related People

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech